drugset / Trial / NCT04377503

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19

NCT04377503

Phase 2 Terminated 30 enrolled Hospital Sao Domingos
RandomizedCrossoverOpen-labelTreatment

Summary

This study compare the efficacy and safety of tocilizumab versus methylprednisolone in the cytokine release syndrome of patients with COVID-19

Timeline

Start
2020-05-01
Primary completion
2020-08-31
Completion
2020-11-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 0.5 mg/kg
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous